RS61480B1 - Primena fk506 za lečenje plućne arterijske hipertenzije - Google Patents
Primena fk506 za lečenje plućne arterijske hipertenzijeInfo
- Publication number
- RS61480B1 RS61480B1 RS20210239A RSP20210239A RS61480B1 RS 61480 B1 RS61480 B1 RS 61480B1 RS 20210239 A RS20210239 A RS 20210239A RS P20210239 A RSP20210239 A RS P20210239A RS 61480 B1 RS61480 B1 RS 61480B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- pulmonary arterial
- subject
- arterial hypertension
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
| EP12779354.5A EP2704711B1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61480B1 true RS61480B1 (sr) | 2021-03-31 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210239A RS61480B1 (sr) | 2011-05-02 | 2012-04-30 | Primena fk506 za lečenje plućne arterijske hipertenzije |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (https=) |
| EP (3) | EP3821891B1 (https=) |
| JP (1) | JP6177765B2 (https=) |
| AU (2) | AU2012250974B9 (https=) |
| CA (1) | CA2834368C (https=) |
| CY (1) | CY1123900T1 (https=) |
| DK (2) | DK3821891T3 (https=) |
| ES (2) | ES2954905T3 (https=) |
| FI (1) | FI3821891T3 (https=) |
| HR (1) | HRP20210245T1 (https=) |
| HU (1) | HUE053229T2 (https=) |
| LT (1) | LT2704711T (https=) |
| PL (1) | PL2704711T3 (https=) |
| PT (2) | PT2704711T (https=) |
| RS (1) | RS61480B1 (https=) |
| SI (1) | SI2704711T1 (https=) |
| SM (1) | SMT202100085T1 (https=) |
| WO (1) | WO2012151153A1 (https=) |
| ZA (1) | ZA201307905B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834368C (en) | 2011-05-02 | 2020-02-18 | The Board Of Trustees Of The Leland Stanford Junor University | Use of fk506 for the treatment of pulmonary arterial hypertension |
| CN107427698A (zh) | 2015-01-13 | 2017-12-01 | 维瓦斯公司 | 肺高血压的组合疗法 |
| CN107708695A (zh) * | 2015-05-08 | 2018-02-16 | 维瓦斯公司 | 用于治疗或预防肺高血压的组合物和方法 |
| CN105062976B (zh) * | 2015-08-05 | 2018-05-11 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| JP2020520906A (ja) * | 2017-05-19 | 2020-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肺高血圧症の治療のためのエンザスタウリン及び脆弱性ヒスチジン三連構造（ｆｈｉｔ）増加剤 |
| WO2019185708A1 (en) * | 2018-03-28 | 2019-10-03 | Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| FR2936060B1 (fr) * | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| WO2010047999A2 (en) * | 2008-10-22 | 2010-04-29 | Sam Amer & Co., Inc. | Method for treating pulmonary arterial hypertension |
| CA2834368C (en) | 2011-05-02 | 2020-02-18 | The Board Of Trustees Of The Leland Stanford Junor University | Use of fk506 for the treatment of pulmonary arterial hypertension |
-
2012
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en not_active Ceased
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en not_active Withdrawn
- 2012-04-30 SM SM20210085T patent/SMT202100085T1/it unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US12521379B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12521379B2 (en) | Use of FK506 for the treatment of pulmonary arterial hypertension | |
| DK2523688T3 (en) | ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS | |
| Reichenspurner | Overview of tacrolimus-based immunosuppression after heart or lung transplantation | |
| US20090269337A1 (en) | Compositions and methods for treating diabetes | |
| US20250188148A1 (en) | Methods of administering an activin receptor type iib variant | |
| US12171752B2 (en) | Methods of treating post-COVID condition(s) | |
| KR20050106038A (ko) | 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제 | |
| KR20170103918A (ko) | 폐 고혈압을 위한 병용 요법 | |
| WO2017106584A1 (en) | Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor | |
| WO2016182813A1 (en) | Compositions and methods for the treatment or prevention of pulmonary hypertension | |
| CA3124115A1 (en) | Method for treating drug or alcohol dependency | |
| Grandaliano et al. | Immunosuppression in kidney transplantation | |
| US20260069545A1 (en) | Modified release formulations of ibudilast | |
| KR20230028497A (ko) | 표적화된 방출 리팍시민 조성물 | |
| Levy et al. | Modern Immunosuppressives 11 ed. by H.-J Schuurman, G. Feutren and J.-F. Bach© 2001 Birkhäuser Verlag/Switzerland | |
| Nuria et al. | Immunosuppression and Post-transplant Hyperglycemia | |
| Bakirs et al. | Bibliography Current World Literature Vol 18 No 5 September 2009 |